Successful Use of Rocuronium and Sugammadex in a Patient with Myasthenia Gravis Undergoing Cervical Anterior Fusion: A Case Report

Ki Tae Jung¹, Keum Young So², Hyeon Song³, Sang Hun Kim⁴*

¹Associate Professor, Department of Anesthesiology and Pain Medicine, Chosun University, School of Medicine, Republic of Korea
²Professor, Department of Anesthesiology and Pain Medicine, Chosun University, School of Medicine, Republic of Korea
³Resident, Department of Anesthesiology and Pain Medicine, Chosun University Hospital, Republic of Korea
⁴Associate Professor, Department of Anesthesiology and Pain Medicine, Chosun University, School of Medicine, Republic of Korea

*Corresponding Author: Sang Hun Kim, Department of Anesthesiology and Pain Medicine, Chosun University, School of Medicine, Republic of Korea, Email: ksh3223@chosun.ac.kr

Abstract: The anesthetic management of patients with myasthenia gravis (MG) is usually challenging in elective surgery. Patients with MG exhibit a higher sensitivity to neuromuscular blockers, and very careful drug titrations were required under closely neuromuscular monitoring if neuromuscular blocker is essential for surgery and anesthesia. Patients are at risk of postoperative residual curarization if nondepolarizing neuromuscular blockers are used. So, anesthesiologists prefer spontaneous recovery and extubation after demonstration of adequate parameters. Nowadays some author recommended using sugammadex as a safe and reliable option for reversal of neuromuscular blocker in patients with MG. We present a case of woman receiving rocuronium under train-of-four monitoring for anterior fusion due to herniated cervical disc with MG, and she was subsequently reversed with sugammadex and extubated on postoperative successfully without any respiratory problems.

Keywords: Myasthenia gravis, Rocuronium, Spine surgery, Sugammadex, Train-of-four.

1. INTRODUCTION

Myasthenia gravis (MG) is an autoimmune disorder caused by failure of transmission of the neuromuscular junction leads to an unpredictable response to neuromuscular blockers, which is twice common in women than men [1-3]. MG is characterized by weakness and fatigue of skeletal muscle that it worsens with repetitive exercise while it improves with rest after administration of anticholinesterase medication [4, 5]. Surgery and anesthesia in patients with myasthenia gravis is associated with markedly increased risk of death and post-operative complications, including prolonged ventilation in intensive care [5, 6]. Patients with MG exhibit a higher sensitivity to neuromuscular blockers and very careful drug titrations were required[7]. Patients are at risk of postoperative residual curarization if non depolarizing neuromuscular blockers are used. Therefore, neuromuscular blocker should be avoided, or shorter-acting drugs may chose under closely neuromuscular monitoring if neuromuscular blocker is essential for surgery and anesthesia [8]. In addition, anesthesiologists prefer spontaneous recovery and extubation after demonstration of adequate parameters (e.g., head life, tongue protrusion) [9, 10]. Nowadays some author recommended using sugammadex as a safe and reliable option for reversal of neuromuscular blocker in patients with MG [3, 11].

We present a case of woman receiving rocuronium for anterior fusion for herniated cervical disc with MG, and she was subsequently reversed with sugammadex and extubated on postoperative successfully without any respiratory problems.
Successful Use of Rocuronium and Sugammadex in a Patient with Myasthenia Gravis Undergoing Cervical Anterior Fusion: A Case Report

2. CASE REPORT

A 55-year-old woman (60 kg) underwent anterior fusion for herniated cervical disc. Her past medical history included a diagnosis of myasthenia gravis, diagnosed 7 years previously for which she was taking 180 (60 x 3) mg pyridostigmine daily. After premedication with intramuscular midazolam 2.5 mg and her usual dose of pyridostigmine 30 min prior to the induction of anesthesia, she was transported to the operating room. Prior to the induction of anesthesia, the standard patient monitoring devices such as an electrocardiogram, non-invasive blood pressure, end-tidal partial pressure of carbon dioxide (ETCO₂), and peripheral pulse oximetry were applied. And then, TOF-Watch SX (Organon, Dublin, Ireland) was applied for assessment of neuromuscular function by acceleromyography of the adductor pollicis muscle with Train-of-Four (TOF) according to the manufacturer’s recommendation. Anesthesia was induced with remifentanil and propofol at target effect-site concentrations of 3.0 ng/ml and 3.0 μg/ml with a target-controlled infusion pump (Orchestra®; Fresenius Vial, Brezins, France). One minute after equilibration of the target plasma and effect-site concentrations of propofol and remifentanil, the supramaximal stimulus current (30 mA) needed to achieve the maximal response of adductor pollicis muscle was obtained. Video-score-assisted endotracheal intubation was performed after injection of rocuronium 25 mg (0.4 mg/kg, ideal body weight) over 5 to 10 seconds with pretreatment of lidocaine 30 mg. For the maintenance of anesthesia, the target effect-site concentration of propofol and remifentanil was adjusted to maintain mean blood pressure less than 20% change and the bispectral index score in the range of 40 to 60. The settings of mechanical ventilation with 50% oxygen-air mixture were also adjusted to maintain the ETCO₂ between 35-45 mmHg. Additional rocuronium 5 mg was used to maintain neuromuscular blockade less than TOF of 0.5. The surgery lasted for 3.75 hours, during which time six boluses of rocuronium 5 mg were given. The neuromuscular block was reversed with Sugammadex 3 mg/kg at the end of the surgery, at which TOF ratio was 0.64. She was successfully extubated without problem and transferred to the recovery room after confirming a TOF ratio of 0.9. Postoperatively she was managed in a high dependency setting with close monitoring of respiration, swallow and cough. Pyridostigmine was continued at the preoperative dose. He was discharged without any complications on postoperative 4 days.

3. DISCUSSION

The use of neuromuscular blockers in patients with MG has been a controversial topic, and it is difficult to determine the optimal amount of muscle relaxants required in these patients. Hence, there is an increasing trend of no neuromuscular blocker techniques in such patients who undergo surgery [12], but neuromuscular blockers should not be avoided in these patients if they require endotracheal intubation [11].

Non-depolarizing neuromuscular blockers have been known to be sensitive in patients with MG [7]. The more severe disease and the higher the dose of pyridostigmine, the more sensitive the patient was toward non-depolarizing NMBA [13]. We may choose shorter-acting neuromuscular blockers and use them under closely neuromuscular monitoring if neuromuscular blocker is essential for surgery and anesthesia [8]. When required, small doses (10-25% of ED₉₅) of intermediate-acting neuromuscular blockers are titrated for both intubation and surgical relaxation [8]. However, roughly 50% of the standard dose is probably adequate, and nearly all patients have a prolonged recovery [14]. Rocuronium 0.15 mg/kg, which is 50% of ED₉₅, resulted in complete neuromuscular block within 120s, while it only produced 30-50% neuromuscular block within 240 s in normal patients [15]. In addition, 25% recovery of neuromuscular transmission occurred after 20 min, while it was more rapid in normal patients [15]. Thus, they suggested that neuromuscular transmission must be monitored carefully in order to titrate the required dose of rocuronium and to ensure complete reversal of neuromuscular block [15].

For recovery from anesthesia in patients with MG, some author recommended using sugammadex as a safe and reliable option for reversal of neuromuscular blocker in patients with MG [3, 11, 16], whether or not to reverse residual neuromuscular blockade at the end of surgery is controversial [8]. The administration of sugammadex for reversal of neuromuscular...
blocker is useful to eliminate the risk of residual neuromuscular blockade in patients with MG [17]. Most case reports showed that neuromuscular blocker reversal using sugammadex seemed to be a safe, rapid, efficient, and reliable option without signs of postoperative residual neuromuscular block in patients with MG [17-21].

Some cases may require higher dose of rocuronium for rapid sequence induction and patient’s safety during intraoperative period in patients with MG. A single bolus of rocuronium 0.5 mg/kg administered to facilitate tracheal intubation was required no maintenance doses of rocuronium, and the neuromuscular blockade was considered adequate throughout surgery [3]. Even though deep rocuronium-induced neuromuscular blockade was also effectively and safely reversed after administration of sugammadex 2 mg/kg at TOF ratio of 0.3, and TOF ratio was reached 0.92 within 3 min after its administration as enough time as prompt weaning from mechanical ventilation postoperatively [3]. The neuromuscular function after injection of rocuronium 0.3 mg/kg was rapidly recovered after administration of sugammadex 2 mg/kg in patients with MG [22]. In addition, Casarotti et al. [23] also suggested that full-dose rocuronium and reversal with sugammadex was the best combination that reconciled the need for rapid onset neuromuscular block while allowing a fast, effective, and reliable reversal at the end of surgery [23].

There is controversy whether cholinesterase inhibitor medication should be continued until the time of the operation, if patients are reliant on their cholinesterase inhibitor medication it should probably be continued perioperatively [4]. Continuation of cholinesterase inhibitors preoperatively does not affect the efficacy of the reversal of neuromuscular block by sugammadex and therefore optimal muscle function is preserved [17].

In this case, we continued her usual dose of pyridostigmine and performed neuromuscular block by rocuronium 0.4 mg/kg. We gave rocuronium 5 mg as additional bolus doses during anesthesia to maintain neuromuscular blockade less than TOF of 0.5. Under monitoring of TOF ratio. For reversal, our patient received sugammadex 2 mg/kg which provided adequate reversal of rocuronium-induced neuromuscular block, which was confirmed by TOF ratio or 0.9.

4. CONCLUSION

To the best of our knowledge, this is the first reported case in the literature in which sugammadex was given in patient with MG undergoing cervical anterior fusion. Sugammadex provide effective reversal of rocuronium-induced neuromuscular block, which was titrated monitoring of neuromuscular function, in patients with MG well-controlled by continuation treatment of pyridostigmine until day surgery. Thus, we suggest that rocuronium-induced neuromuscular block should be titrated monitoring of neuromuscular function, and administration of sugammadex could be routinely considered as part of the anesthesia management in patients with MG.

REFERENCES

Successful Use of Rocuronium and Sugammadex in a Patient with Myasthenia Gravis Undergoing Cervical Anterior Fusion: A Case Report


Copyright: © 2017 Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.